To include your compound in the COVID-19 Resource Center, submit it here.

AbbVie, Calibr to develop universal CAR T therapies

AbbVie Inc. (NYSE:ABBV) and the California Institute for Biomedical Research (La Jolla, Calif.) partnered to develop universal CAR T therapies using the non-profit's switchable CAR T technology to treat hematological

Read the full 304 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE